SARS-CoV-2 Infection Clinical Trial
Official title:
A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.
This study will evaluate the efficacy of the Moderna COVID-19 vaccine against SARS-CoV-2 infection, as well as its effect on peak nasal viral load as a measure of infection and a proxy of infectiousness, in adults aged 18-29. In the Main study, up to 12,000 participants will be randomized 1:1 to Immediate Vaccination Group 1 (at Months 0 and 1) or Standard of Care Group 2, with vaccination given at Months 4 and 5 if not received off-study previously. Up to an additional 6,000 participants will be enrolled into the Vaccine Declined Group 3 and will also be offered vaccine at Months 4 and 5. Additional study visits for Group 1 will occur at Months 2 and 4; for Groups 2 and 3, at Months 0 and 2. Study visits may include medical history, vaccine injections, blood collection, nasal swab, SARS-CoV-2 screening, COVID-19 symptom check, and questionnaires. In addition to the main study participants, the study will also evaluate infectiousness following close contacts with main study participants. Study procedures for close contacts include questionnaires and blood samples; for those who become SARS-CoV-2 infected, study procedures will also include nasal swabs. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04593641 -
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
|
Phase 1 | |
| Recruiting |
NCT05200754 -
Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04583995 -
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
|
Phase 3 | |
| Recruiting |
NCT06255860 -
SARS-COV-2 Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study
|
||
| Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
| Recruiting |
NCT05012826 -
Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID
|
N/A | |
| Completed |
NCT05007236 -
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
|
Phase 2 | |
| Recruiting |
NCT06026514 -
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
|
Phase 1 | |
| Completed |
NCT05523739 -
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
|
Phase 1 | |
| Suspended |
NCT04738136 -
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
|
Phase 2 | |
| Recruiting |
NCT04584658 -
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
|
||
| Recruiting |
NCT04547114 -
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
|
||
| Completed |
NCT05119348 -
Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
|
N/A | |
| Completed |
NCT05096962 -
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
|
||
| Recruiting |
NCT04534400 -
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
|
||
| Completed |
NCT04527354 -
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
|
Phase 2 | |
| Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
| Completed |
NCT05077176 -
Phase 3 Booster Vaccination Against COVID-19
|
Phase 3 | |
| Completed |
NCT05584189 -
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
|
N/A |